Abstract
Adherence to pharmacologic therapy of hypertension is low (in the range of 50–70%) and has important implications both for blood pressure control and cardiovascular complications. Based on a review of the literature using the levels of evidence grading technique, determinants of adherence to the pharmacologic therapy of hypertension have been assessed. Additionally, interventions to improve compliance were evaluated. Patientcentred, health care provider-centred and drug-specific factors have all been shown to affect adherence rates. We conclude that the extent of adherence to pharmacologic therapy is modifiable. Measurable improvements in adherence can be obtained from simplified medication regimens and a combination of behaviour strategies, including the tailoring of pill-taking to patients’ daily habits and rituals, the advocacy of self-monitoring of pills and blood pressure, and the institution of reward systems.
Résumé
L’observance des pharmacothérapies pour le traitement de l’hypertension est faible (de l’ordre de 50 à 70 %) et a des implications importantes tant sur le contrôle de la tension artérielle que sur les complications cardiovasculaires. À partir d’un examen de la literature se servant des niveaux de la technique de graduation des preuves, on a évalué les determinants de l’observance des pharmacothérapies pour le traitement de l’hypertension. En outre, on a aussi évalué les interventions visant à améliorer l’observance. Les facteurs propres aux patients, aux soignants et aux médicaments ont tous indiqué qu’ils avaient une influence sur les taux d’observance. Nous en concluons que la portée de l’observance des pharmacothérapies est modifiable. Des améliorations mesurables de l’observance sont possibles grâce à des régimes médicamenteux simplifiés et à une combinaison de stratégies de comportement comprenant l’adaptation de la prise des médicaments aux habitudes et aux rituals quotidiens des patients, l’encouragement de l’autosurveillance de la tension artérielle et de la prise des médicaments, ainsi que l’établissement d’un système de récompenses.
References
- 1.Haynes RB. Improving patient compliance in the management of hypertension. In: Kaplan NM, Ram CV, editors. Individualized Therapy of Hypertension. New York: Marcel Dekker Inc.; 1995. pp. 257–73. [Google Scholar]
- 2.Luscher TF, Vetter H, Siegenthaler W, Vetter W. Compliance in hypertension: facts and concepts. J Hypertension. 1985;3:3–9. [PubMed] [Google Scholar]
- 3.Haynes RB, Taylor W, Sackett DL, et al. Can simple clinical measurements detect patient noncompliance? Hypertension. 1980;2:757–64. doi: 10.1161/01.HYP.2.6.757. [DOI] [PubMed] [Google Scholar]
- 4.Logan AG, Achber C, Milne B, et al. Work-site treatment of hypertension by specially trained nurses. Lancet. 1979;11:1175–78. doi: 10.1016/S0140-6736(79)92397-3. [DOI] [PubMed] [Google Scholar]
- 5.Morisky DE, Levine DM, Green LW, et al. Five-year blood pressure control and mortality following health education for hypertensive patients. Am J Public Health. 1963;73:153–62. doi: 10.2105/AJPH.73.2.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of β-blockers. JAMA. 1990;263:1653–57. doi: 10.1001/jama.1990.03440120075040. [DOI] [PubMed] [Google Scholar]
- 7.Meinikow J, Kiste C. Patient compliance and medical research: Issues in methodology. J Gen Int Med. 1994;9:96–105. doi: 10.1007/BF02600211. [DOI] [PubMed] [Google Scholar]
- 8.Levine DM, Green LW, Deeds SG, et al. Health education for hypertensive patients. JAMA. 1979;41:1700–3. doi: 10.1001/jama.1979.03290420026019. [DOI] [PubMed] [Google Scholar]
- 9.Muhlhauser L, Sawicki PT, Dicilurgeit U, et al. Evaluation of a structured treatment and teaching programme on hypertension in general practice. Clin & Exper Hypertension. 1993;15:125–42. doi: 10.3109/10641969309041615. [DOI] [PubMed] [Google Scholar]
- 10.Webb PA. Effectiveness of patient education and psychological counselling in promoting compliance and control among hypertensive patients. J Fam Pract. 1980;10:1047–55. [PubMed] [Google Scholar]
- 11.Berger BA, Stanton AL, Feley BG, et al. The effectiveness of an educational program to teach pharmacists to counsel hypertensive patients and influence adherence. J Pharm Marketing and Manage. 1990;5:27–41. doi: 10.3109/J058v05n02_03. [DOI] [Google Scholar]
- 12.Nessman DG, Carnahan JE, Nugent CA. Increasing compliance: Patient-operated hypertension groups. Arch Intern Med. 1980;140:1427–30. doi: 10.1001/archinte.1980.00330220015009. [DOI] [PubMed] [Google Scholar]
- 13.Johnson AL, Taylor DW, Sackett DL, et al. Self-recording blood pressure in the management of hypertension. Can Med Assoc J. 1978;119:1034–39. [PMC free article] [PubMed] [Google Scholar]
- 14.Baird MG, Bentley-Taylor MM, Carruthers SG, et al. A study of efficacy, tolerance and compliance of once-daily versus twice-daily metoprolol (Betaloc) in hypertension. Betaloc Compliance Canadian Cooperative Study Group. Clin Invest Med. 1984;7:95–102. [PubMed] [Google Scholar]
- 15.Becker LA, Glanz K, Sobel E, et al. A randomized trial of special packaging of antihypertensive medications. J Fam Pract. 1986;22:357–61. [PubMed] [Google Scholar]
- 16.Haynes RB, Sackett DL, Gibson ES, et al. Improvement of medication compliance in uncontrolled hypertension. Lancet. 1976;1:1265–68. doi: 10.1016/S0140-6736(76)91737-2. [DOI] [PubMed] [Google Scholar]
- 17.Sackett DL, Haynes RB, Gibson ES, et al. Randomized clinical trial strategies for improving medication compliance in primary hypertension. Lancet. 1975;1:1205–7. doi: 10.1016/S0140-6736(75)92192-3. [DOI] [PubMed] [Google Scholar]
- 18.Woolf SH, Battista RN, Anderson GM, et al. Assessing the clinical effectiveness of preventive maneuvers: Analytic principles and systematic methods in reviewing evidence and developing clinical practice recommendations. J Clin Epidemiol. 1990;43:891–905. doi: 10.1016/0895-4356(90)90073-X. [DOI] [PubMed] [Google Scholar]